PFE — Pfizer Inc.

Pfizer Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Full Year 2025 Revenues: $62.6 billion, down 2% from $63.6 billion in 2024. Excluding COVID-19 products, operational revenue grew 6%.
• Adjusted Diluted EPS: $3.22, up from $3.11 in 2024, exceeding expectations. Reported diluted EPS was $1.36, down from $1.41.
• Q4 2025 Revenues: $17.6 billion, a 3% operational decline year-over-year, primarily due to a 40% drop in COVID product sales.
• Non-COVID Product Performance: Grew 9% operationally in Q4, driven by products like Abrisvo, Eliquis, Prevnar, and Vyndaqel.
• Adjusted Gross Margin: 71% for Q4, with full-year margins at 76%.

2. Strategic Updates and Business Highlights

• Pfizer executed 40 approvals and initiated 11 pivotal studies in 2025, enhancing its pipeline.
• Key acquisitions (Seagen, Metaira, Biohaven) are expected to drive future growth, particularly in oncology and chronic weight management.
• The FDA approved PATCEV for muscle-invasive bladder cancer, expanding the addressable patient population significantly.
• The company is focusing on leveraging AI across R&D, manufacturing, and commercial operations to enhance productivity.

3. Forward Guidance and Outlook

• 2026 Guidance: Revenues expected between $59.5 billion and $62.5 billion, with adjusted diluted EPS projected between $2.80 and $3.00.
• Anticipated continued revenue decline from COVID products, projected at around $5 billion in 2026.
• Non-COVID product revenue is expected to grow approximately 4% operationally year-over-year, despite anticipated generic competition impacting some products.

4. Bad News, Challenges, or Points of Concern

• Significant revenue decline in COVID-19 products due to reduced demand and lower infection rates.
• The company is entering a period of patent expirations (LOEs) from 2026 to 2028, which could pressure revenues.
• Approximately $4.4 billion in non-cash intangible asset impairments were recorded, reflecting strategic decisions to deprioritize certain development programs.
• Competitive pressures in the oncology market, particularly with PD-1/VEGF therapies, as the market becomes increasingly crowded.

5. Notable Q&A Insights

• VSPR III Data: The tolerability profile for the GLP-1 receptor agonist showed no significant increase in severe adverse events when switching from weekly to monthly dosing. Full data will be presented at ADA.
• Market Potential: The obesity market is projected to be worth $150 billion, with a significant portion of demand coming from outside the US.
• Integration of Seagen: The integration is progressing well, with several programs accelerated and new studies planned.
• AI Investments: Pfizer is embedding AI across multiple functions to enhance productivity and efficiency, with metrics in place to measure success.

Overall, Pfizer's performance in 2025 reflects strong execution and strategic positioning for future growth, despite challenges from declining COVID product sales and upcoming patent expirations. The company is focused on leveraging its robust pipeline and recent acquisitions to drive long-term shareholder value.